Progress in ALS Research: U.S. House Passes ACT for ALS Reauthorization Act

The ALS Network has expressed its enthusiastic support following the U.S. House of Representatives' decisive action of approving the Accelerating Access to Critical Therapies (ACT) for ALS Reauthorization Act. This landmark bipartisan legislation, propelled by the efforts of Representatives Ken Calvert and Mike Quigley, aims to extend critical support for ALS research and therapies until 2031.

This House vote is significant as it provides hope for countless individuals and families impacted by ALS, a progressive neurodegenerative disease. The current law is set to expire on September 30, 2026, which has catalyzed the ALS Network to call for urgent action from the Senate. The reauthorization aims to ensure the continuation of vital programs that have been pivotal in advancing research and improving access to investigational therapies for ALS patients, especially those unable to partake in standard clinical trials.

The ACT for ALS initiative introduced a patient-focused framework that has significantly accelerated research and expanded access to therapies that could make a difference in the lives of ALS patients. Given the nature of ALS, where effective treatment options are scarce and time is of the essence, these expansions in access and research are critical.

Sheri Strahl, President and CEO of the ALS Network, acknowledged the passing of this act as a meaningful milestone for those battling ALS and their families. She expressed her profound gratitude to the representatives for their bipartisan leadership, stating that the ACT has opened avenues for new treatments and therapeutic developments. Strahl emphasized that the continued support from the House will facilitate the important work ahead for the ALS community.

In addition, the ALS Network credited the dedicated advocates and organizations within the ALS community whose persistent efforts were instrumental in rallying bipartisan support for the legislation. Their engagement and narratives have played a crucial role in keeping the plight of ALS patients in the public and legislative eye.

However, the urgency for Senate action cannot be overstated. The impending expiration of the current law poses a threat to the ongoing progress in ALS research and therapy access. If the Senate does not act promptly, essential programs may begin to wind down, resulting in a setback for researchers and families who depend on these efforts for hope.

As the conversation approaches the Senate, the ALS Network is rallying support to challenge lawmakers to honor the bipartisan momentum established in the House and advance the ACT for ALS. The outcome could significantly influence future research initiatives and the availability of therapies vital to those afflicted by ALS.

About the ALS Network

Established to champion the rights and needs of ALS patients, the ALS Network collaborates with the community to spearhead the development of prevention strategies, therapies, and potential cures. The organization also ensures the provision of quality care and improvements in health outcomes for individuals and families affected by the disease. It operates primarily in California and Hawaii, with initiatives extending beyond these borders.

For more information about the ALS Network and its initiatives, visit alsnetwork.org or connect via social media @yourALSnetwork.